FDA Center for Biologics Evaluation and Research, Rockville, MD 20852, USA.
J Virol Methods. 2010 Nov;169(2):322-31. doi: 10.1016/j.jviromet.2010.07.037. Epub 2010 Aug 4.
A blocking-ELISA procedure was used to quantify antibodies in sera of humans immunized with poliovirus vaccines. Titers determined by this method demonstrated an excellent correlation with the results of neutralization test. Testing of serum potency with a panel of type 1 poliovirus strains altered antigenically was used to evaluate the composition of polyclonal sera with respect to the epitope specificity of constituent antibodies. Paratope profiles of various polyclonal sera determined by this new method differed, depending on the type of vaccine used for immunization. Antibodies induced in response to inactivated poliovirus vaccine (IPV) contained antibodies directed primarily against antigenic site 1, while sera from recipients of the oral poliovirus vaccine (OPV) contained antibodies to site 3. Antibodies to antigenic sites 2 and 4 were minor constituents in both types of sera. Pre-immunization sera had paratope profiles similar to OPV-induced antisera, allowing the discrimination between antibodies induced by IPV and maternal antibodies. The new method may be useful for analyzing results of clinical trials and to compare immunity induced by different poliovirus vaccines.
采用阻断 ELISA 法检测了经脊髓灰质炎病毒疫苗免疫的人体血清中的抗体。该方法测定的效价与中和试验结果具有极好的相关性。用一组抗原性改变的 1 型脊髓灰质炎病毒株检测血清效价,用于评估多克隆血清中组成抗体的表位特异性。用这种新方法测定的各种多克隆血清的变构位图谱因所用疫苗的类型而异。针对灭活脊髓灰质炎病毒疫苗 (IPV) 诱导的抗体主要针对抗原表位 1,而口服脊髓灰质炎病毒疫苗 (OPV) 受种者的血清中含有针对表位 3 的抗体。两种血清中的抗体 2 和 4 表位均为次要成分。免疫前血清的变构位图谱与 OPV 诱导的抗血清相似,可区分 IPV 和母体抗体诱导的抗体。这种新方法可用于分析临床试验结果,并比较不同脊髓灰质炎病毒疫苗诱导的免疫。